IP Library Granted Patent US 8,115,002
Granted Patent B2
US 8,115,002 · App. 12/441,397 · Granted Feb 14, 2012

Preparation of substituted morphinan-6-ones and salts and intermediates thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,115,002
App. No.
12/441,397
Granted
Feb 14, 2012
Kind
B2
Abstract

The present invention is directed to processes for the synthesis of morphinan-6-ones and salts, intermediates, and analogs thereof.

Claims (105)

1. A process for the preparation of a ketal (1000), the process comprising converting a hexahydroisoquinoline (800) to a ketal (1000) in a series of steps, the series of steps comprising (a) converting hexahydroisoquinoline (800) to a N-formyl derivative (900) with a formylating agent and (b) converting the N-formyl derivative (900) to the ketal (1000) with a ketalizing agent in the presence of an acid catalyst, whereby the conversion of the hexahydroisoquinoline (800) to the ketal (1000) proceeds without an intermediate crystallization of the N-formyl derivative (900);

wherein the conversion of the hexahydroisoquinoline (800) to the N-formyl derivative (900) produces a formylation product mixture containing the N-formyl derivative (900) and unreacted formylating agent, the unreacted formylating agent being separated from the N-formyl derivative (900) by including in the formylation product mixture a liquid composition having a boiling point that is greater than the boiling point of the formylating agent, and the formylation product mixture being heated to remove unreacted formylating agent and leave the N-formyl derivative (900) dissolved in the liquid composition; and,

wherein the hexahydroisoquinoline (800), the N-formyl derivative (900), and the ketal (1000) correspond to Formulae (800), (900), and (1000), respectively:

wherein:

R 1 and R 7 are independently hydrogen, hydrocarbyl, substituted hydrocarbyl, or —OR 111 ;

R 5 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or —OR 511 ;

R 6 is —OR 511 :

R 2 is hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, or —OR 211 ;

R 3 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or —OR 311 ;

R 4 is hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, or —OR 411 ;

R 66a and R 66b are independently selected from the group consisting of alkoxy and alkylthio or together with the carbon atom to which they are attached form a ketal, dithioketal, or monothioketal;

R 12 is hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, or —OR 121 ;

R 13 is hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, or —OR 511 ;

R 111 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or a hydroxy protecting group;

R 121 is hydrogen, hydrocarbyl, or substituted hydrocarbyl;

R 211 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or a hydroxy protecting group;

R 311 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or a hydroxy protecting group;

R 411 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or a hydroxy protecting group;

R 511 is hydrogen, hydrocarbyl, substituted hydrocarbyl or a hydroxy protecting group; and

—Z— is

2. The process of claim 1 wherein the liquid composition is a solvent having a boiling point that is greater than the boiling point of the formylating agent.

3. The process of claim 1 wherein the liquid composition is the ketalizing agent.

4. The process of claim 1 further comprising converting the ketal (1000) to a haloketal (1100) with a halogenating agent, whereby the conversion of the ketal (1000) to the halo ketal (1100) proceeds without an intermediate crystallization of the ketal (1000); wherein the haloketal (1100) corresponds to Formula (1100):

R 2 is hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, or —OR 211 ;

R 3 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or —OR 311 ;

R 4 is hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, or —OR 411 ;

R 5 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or —OR 511 ;

R 66a and R 66b are independently selected from the group consisting of alkoxy and alkylthio or together with the carbon atom to which they are attached form a ketal, dithioketal, or monothioketal;

R 7 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or —OR 111 ;

R 12 is hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, or —OR 121 ;

R 13 is hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, or —OR 511 ;

R 111 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or a hydroxy protecting group;

R 121 is hydrogen, hydrocarbyl, or substituted hydrocarbyl;

R 211 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or a hydroxy protecting group;

R 311 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or a hydroxy protecting group;

R 411 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or a hydroxy protecting group;

R 511 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or a hydroxy protecting group; and

X is halo.

5. The process of claim 4 wherein the conversion of the N-formyl derivative (900) to the ketal (1000) produces a ketalization product mixture containing the ketal (1000) in the liquid composition and the conversion of the ketal (1000) to the haloketal (1100) proceeds by treating the ketalization product mixture with a halogenating agent to form a halogenation product mixture containing the haloketal (1100).

6. The process of claim 4 wherein the N-formyl derivative (900) is combined with a water immiscible solvent prior to converting the N-formyl derivative (900) to the ketal (1000) with the ketalizing agent.

7. The process of claim 5 further comprising separating the liquid composition from the formylation, ketalization, or halogenation product mixtures by including in the formylation, ketalization, or halogenation product mixtures a water soluble solvent having a boiling point that is greater than the boiling point of the liquid composition, and heating the formylation, ketalization, or halogenation product mixtures to a temperature in excess of the boiling point of the liquid composition to remove the liquid composition and leave the N-formyl derivative (900), the ketal (1000), or the haloketal (1100) dissolved in the water soluble solvent.

8. The process of claim 4 further comprising converting the haloketal (1100) to a haloketone (1200) with a hydrolyzing agent, whereby the conversion of the haloketal (1100) to the haloketone (1200) proceeds without an intermediate crystallization of the haloketal (1100); wherein the haloketone (1200) corresponds to Formula (1200):

R 2 is hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, or —OR 211 ;

R 3 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or —OR 311 ;

R 4 is hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, or —OR 411 ;

R 5 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or —OR 511 ;

R 7 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or —OR 111 ;

R 12 is hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, or —OR 121 ;

R 13 is hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, or —OR 511 ;

R 111 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or a hydroxy protecting group;

R 121 is hydrogen, hydrocarbyl, or substituted hydrocarbyl;

R 211 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or a hydroxy protecting group;

R 311 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or a hydroxy protecting group;

R 411 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or a hydroxy protecting group;

R 511 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or a hydroxy protecting group; and

X is halo.

9. The process of claim 7 wherein the conversion of the N-formyl derivative (900) to the ketal (1000), the ketal (1000) to the haloketal (1100), or the haloketal (1100) to the haloketone (1200) further comprises separating the N-formyl derivative (900), the ketal (1000), or the haloketal (1100) from the water soluble solvent by (i) combining the N-formyl derivative (900), the ketal (1000), or the haloketal (1100) and the water soluble solvent with a water immiscible solvent and an aqueous solution comprising water to form an extraction mixture comprising (A) a water immiscible solvent portion comprising the N-formyl derivative (900), the ketal (1000), or the haloketal (1100) dissolved in the water immiscible solvent, and (B) an aqueous portion comprising solubilized water soluble solvent, and (ii) separating the water immiscible solvent portion from the extraction mixture.

10. The process of claim 8 further comprising converting the haloketone (1200) to a morphinan-6-one (1300) with a cyclizing acid and an acid anhydride, whereby the conversion of the halo ketone (1200) to the morphinan-6-one (1300) proceeds without an intcm1cdiate cyclization of the halo ketone (1200); wherein the morphinan-6-one corresponds to Formula (1300):

R 2 is hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, or —OR 211 ;

R 3 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or —OR 311 ;

R 4 is hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, or —OR 411 ;

R 5 is hydrogen, hydrocarbyl substituted hydrocarbyl, or —OR 511 ;

R 7 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or —OR 111 ;

R 13 is hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, or —OR 511 ;

R 111 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or a hydroxy protecting group;

R 211 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or a hydroxy protecting group;

R 311 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or a hydroxy protecting group;

R 411 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or a hydroxy protecting group;

R 511 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or a hydroxy protecting group; and

X is halo.

11. The process of claim 10 wherein the conversion of the haloketone (1200) to the morphinan-6-one (1300) proceeds in the presence of a water immiscible solvent.

12. The process of claim 11 wherein the conversion of the haloketone (1200) to the morphinan-6-one (1300) proceeds by treating the halogenation product mixture with the cyclizing acid to form the cyclization product mixture containing the morphinan-6-one (1300) in the water immiscible solvent.

13. The process of claim 12 further comprising treating the cyclization product mixture containing the morphinan-6-one (1300) with an acid or base salt to form a morphinan-6-one salt product mixture containing a morphinan-6-one salt (1400); wherein the morphinan-6-one salt (1400) corresponds to Formula (1400):

R 2 is hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, or —OR 211 ;

R 3 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or —OR 311 ;

R 4 is hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, or —OR 411 ;

R 5 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or —OR 511 ;

R 7 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or —OR 111 ;

R 13 is hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, or —OR 511 ;

R 111 is hydrogen, hydrocarbyl, or substituted hydrocarbyl;

R 121 is hydrogen, hydrocarbyl, or substituted hydrocarbyl;

R 211 is hydrogen, hydrocarbyl or substituted hydrocarbyl;

R 311 is hydrogen, hydrocarbyl or substituted hydrocarbyl;

R 411 is hydrogen, hydrocarbyl or substituted hydrocarbyl;

R 511 is hydrogen, hydrocarbyl, or substituted hydrocarbyl;

X is halo; and

Y is a counterion.

14. The process of claim 1 wherein the formylating agent is formic acid, propyl formate, or butyl formate.

15. The process of claim 1 wherein the formylation product mixture is heated to a temperature of at least about 70° C.

16. The process of claim 4 wherein the conversion of the N-formyl derivative (900) to the ketal (1000) proceeds in the presence of a water scavenger.

17. The process of claim 4 wherein the conversion of the ketal (1000) to the haloketal (1100) proceeds in the presence of a water scavenger.

18. The process of claim 4 wherein the conversion of the N-formyl derivative (900) to the ketal (1000) and the conversion of the ketal (1000) to the haloketal (1100) each proceed in the presence of a water scavenger.

19. The process of claim 18 wherein the water scavenger corresponds to the formula: R Y C(OR Z ) 3 , wherein R Y is hydrogen or hydrocarbyl and R Z is hydrocarbyl.

20. The process of claim 1 wherein the ketalizing agent is selected from the group consisting of alkanols, alkanediols, and thiols.

21. The process of claim 4 wherein the halogenating agent is selected from the group consisting of chlorine (Cl 2 ), bromine (Br 2 ), N-bromoacetamide (NBA), N-bromosuccinimide (NBS), 1,3-dibromo-5,5-methylhydantoin (OBDMH), 1,3-dichloro-5,5-methylhydantoin (DCDMH), N-chlorosuccinimide (NCS), pyridinium tribromide, and combinations thereof.

22. The process of claim 8 wherein the hydrolyzing agent is selected from the group consisting acetic acid, oxalic acid, formic acid, propanoic acid, butanoic acid, pentanoic acid, benzoic acid, hydrochloric acid, sulfuric acid, methanesulfonic acid, hydrobromic acid, trifluoroacetic acid, and combinations thereof.

23. The process of claim 2 wherein the solvent is selected from the group consisting of chlorobenzene, toluene, butyl acetate, dimethoxyethane, acetonitrile, 1,2-dichloroethane, 1,4-dioxane, ethyl acetate, propyl acetate, ethanol, 1-butanol, 2-butanol, 1-propanol, 2-propanol, tert-butanol, acetic acid, 2-methoxyethanol, and combinations thereof.

24. The process of claim 7 wherein the water soluble solvent is selected from the group consisting of dimethylformamide (DMF), dimethylsulfoxide (DMSO), dimethylacetamide (DMAC), N-methylpyrrolidinone (NMP), 1,2-ethanediol, isopropanol, isobutanol, tert-butanol, and n-butanol.

25. The process of claim 10 wherein the cyclizing acid comprises a strong acid, a super acid, and combinations thereof.

26. The process of claim 1 wherein R 2 is hydrogen or —OR 211 ; and R 211 is hydrogen, alkyl, acyl, alkaryl, aryl, or a hydroxyl protecting group.

27. The process of claim 26 wherein R 3 is hydrogen or —OR 311 ; and R 311 is hydrogen, alkyl, acyl, alkaryl, aryl, or a hydroxyl protecting group.

28. The process of claim 27 wherein R 4 is hydrogen or —OR 411 ; and R 411 is hydrogen, alkyl, acyl, alkaryl, aryl, or a hydroxyl protecting group.

29. The process of claim 1 wherein R 2 is hydrogen; R 3 is —OR 311 ; R 4 is —OR 411 ; R 311 is alkyl; and R 411 is hydrogen.

30. The process of claim 29 wherein R 1 , R 5 , R 7 , R 12 , and R 13 are hydrogen.

31. The process of claim 4 wherein X is bromo.

Assignments (11)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →